Aspergillus biofilms were prepared from Aspergillus fumigatus, Aspergillus flavus, and Aspergillus terreus via a 96-well platebased method, and the combined antifungal activity of tacrolimus with azoles or amphotericin B against Aspergillus biofilms was investigated via a broth microdilution checkerboard technique system. Our results suggest that combinations of tacrolimus with voriconazole or amphotericin B have synergistic inhibitory activity against Aspergillus biofilms. However, combinations of tacrolimus with itraconazole or posaconazole exhibit no synergistic or antagonistic effects.
I
nvasive fungal infections caused by Aspergillus spp. have already become one of the major causes of death in immunocompromised patients in recent years (1) . Recent studies have suggested that biofilm formation by Aspergillus spp. may be one of the most important virulence factors in invasive pulmonary aspergillosis and aspergilloma (2, 3) . The MICs of antifungal agents required to kill biofilm structures of Aspergillus spp. are much higher than those required to kill the planktonic forms of the fungus (4, 5) . It has been reported that combinations of tacrolimus, which targets calcineurin, a Ca 2ϩ -calmodulin-dependent protein phosphatase, and antifungal agents have synergistic activity against pathogenic fungi, such as Candida albicans, Mucorales, and Aspergillus fumigatus (6) (7) (8) . Therefore, it is reasonable to determine whether the combination of tacrolimus and amphotericin (AMB) or azoles would generate a synergistic inhibitory effect against Aspergillus biofilms.
In the present study, Aspergillus biofilms were prepared from 20 strains of Aspergillus spp., including 10 strains of Aspergillus fumigatus, 8 strains of Aspergillus flavus, and 2 strains of Aspergillus terreus, via a 96-well plate-based method (9) . The Aspergillus strains were all clinical isolates from patients with invasive aspergillosis and identified by molecular and morphological methods. The individual MICs of tested drugs, including tacrolimus, itraconazole (ITC), posaconazole (POC), voriconazole (VRC), and AMB, for planktonic cells of Aspergillus spp. were determined according to the M38-A2 method (10) . The effects of tacrolimus and antifungals alone, and combinations of antifungals with tacrolimus, on Aspergillus biofilms were assessed by a checkerboard method with biofilms formed in the wells of microtiter plates and an XTT (2,3-bis-[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide)-based colorimetric assay (11) . All antifungal drugs and chemical agents were purchased in powder form from Sigma Chemical Co. (St. Louis, MO) and prepared as outlined in the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method M38-A2 (10). The working concentration ranges of tacrolimus, ITC, VRC, POC, and AMB were 2 to 256 g/ml, 0.5 to 256 g/ml, 0.5 to 256 g/ml, 0.5 to 256 g/ml, and 0.06 to 32 g/ml, respectively. The sessile MICs (SMIC 50 and SMIC 80 ) were defined as the concentrations at which a 50% or 80% decrease, respectively, in optical density (OD) would be detected in comparison to the controls (11) . The interaction of tacrolimus with AMB or azoles referred to the fractional inhibitory concentration index (FICI), which was classified as follows: FICI of Յ0.5, synergy; FIC of Ͼ0.5 to Յ4, no interaction; FICI of Ͼ4, antagonism (12) . All experiments were conducted in triplicate.
The ranges of the MICs of individual tested drugs for isolates of planktonic Aspergillus spp. were Ն256 g/ml for tacrolimus, 1 to 4 g/ml for ITC, 0.5 to 2 g/ml for VRC, 0.125 to 2 g/ml for POC, and 0.125 to 4 g/ml for AMB ( Table 1 ). The ranges of the SMIC 50 for Aspergillus biofilms were Ն256 g/ml for tacrolimus, 16 to Ն256 g/ml for ITC, 8 to Ն256 g/ml for VRC, 2 to Ն256 g/ml for POC, and 2 to 32 g/ml for AMB, while the ranges of the SMIC 80 were Ն256 g/ml for tacrolimus, 64 to Ն256 g/ml for ITC, 32 to Ն256 g/ml for VRC, 32 to Ն256 g/ml for POC, and 2 to 32 g/ml for AMB ( Table 2, Table 3 ). As described in previous studies, the MICs required to kill biofilm structures of Aspergillus spp. are much higher than those required to kill the planktonic forms (4, 5) . However, when tacrolimus was combined with AMB against Aspergillus biofilms, the SMIC 50 ranges of AMB and tacrolimus decreased to 0.25 to 4 g/ml and 2 to 64 g/ml, respectively, while the SMIC 80 ranges decreased to 0.25 to 4 g/ml and 2 to 32 g/ml, respectively (Table 2 ). Based on the FICIs calculated from the SMIC 50 , favorable synergistic effects were shown against biofilms of 12 isolates of Aspergillus spp., including 5 strains of A. fumigatus (5 of 10) and 7 strains of A. flavus (7 of 8) . Based on the FICIs calculated from the SMIC 80 , favorable synergistic effects were shown against biofilms of 14 isolates of Aspergillus spp., including 6 strains of A. fumigatus (6 of 10) and all strains of A. flavus. However, no synergistic effect against A. terreus biofilms was observed. For the combination of tacrolimus and VRC, the SMIC 50 of VRC and tacrolimus decreased to 1 to 128 g/ml and 2 to 16 g/ml, respectively. The FICIs based on the SMIC 50 revealed syn-ergistic effects against biofilms of 10 isolates of Aspergillus spp., including 5 strains of A. fumigatus (5 of 10), 4 strains of A. flavus (4 of 8), and 1 strain of A. terreus (1 of 2) ( Table 2 ). The SMIC 80 of VRC and tacrolimus in this combination also decreased to 1 to 128 g/ml and 2 to 16 g/ml, respectively. The FICIs based on the SMIC 80 revealed synergistic effects against biofilms of 13 strains, including 7 strains of A. fumigatus (7 of 10), 5 strains of A. flavus (5 of 8), and 1 strain of A. terreus (1 of 2). No synergistic effect was observed when tacrolimus was combined with ITC or POC (Table  3) . No antagonistic effect was observed against Aspergillus biofilms with these combinations.
Although our results revealed an unfavorable antifungal effect of tacrolimus alone against planktonic cells and biofilm forms of all isolates of Aspergillus spp. studied, in vitro synergism against most of the biofilms generated from A. fumigatus isolates and from nonfumigatus Aspergillus isolates tested were observed when tacrolimus was combined with AMB or VRC, in agreement with the findings for other fungal species (7, 8, 13) . This drug synergism may be attributable to the following effects: tacrolimus, the calcineurin inhibitor, renders the azole fungicidal rather than simply fungistatic, and membrane perturbation by antifungal inhibition of ergosterol biosynthesis increases intracellular calcineurin inhibitor concentrations (8) . In addition, the molecular chaperone Hsp90 has been implicated as a key regulator of biofilm dispersion and drug resistance, and an Hsp90-activated calcineurin signaling pathway has been reported to be associated with antifungal resistance in Aspergillus biofilms (14, 15) . We speculate that the decreased SMIC 50 and SMIC 80 of tacrolimus may result from the membrane perturbation and stress response due to AMB or VRC, and the decreased SMIC 50 and SMIC 80 of AMB and VRC may result from the inhibition of the Hsp90-activated calcineurin signaling pathway. In summary, our results suggest that calcineurin pathway inhibition in combination with classical antifungal agents has therapeutic potential in Aspergillus biofilm-associated fungal infections. Due to the immunosuppressive properties of calcineurin inhibitors, the clinical use would ultimately require a selectively fungal calcineurin pathway-targeted agent without collateral effects on human cells.
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